TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06209632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: 30 minutes of intervention, twice a week, and a total of 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contralaterally controlled functional electrical stimulation
Description: 30 minutes of intervention, twice a week, and a total of 12 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: contralaterally controlled functional electrical stimulation
Description: 30 minutes of intervention, twice a week, and a total of 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: 50 minutes of intervention, twice a week, and a total of 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: 50 minutes of intervention, twice a week, and a total of 12 weeks

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: conventional physiotherapy
Description: 50 minutes of intervention, twice a week, and a total of 12 weeks
Study: NCT05334394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Technique
Description: Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Exercise is recommended by physical therapists for most chronic low back pain patients.
Study: NCT05849077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sat75
Description: As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sat50
Description: As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
Study: NCT04827901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XEN1101
Description: two 10 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT05652647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral [14C]PF-07081532
Description: A single oral dose of \[14C\]PF-07081532, will be administered as a liquid formulation in study period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PF-07081532 and IV [14C]PF-07081532
Description: In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-07081532 will be administered via intravenous infusion.
Study: NCT05100004

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Theta Burst Stimulation
Description: Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system.
Study: NCT04743791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
Study: NCT05052580

Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 Testing
Description: Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
Study: NCT06336785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane line of soft tissue fillers and Dysport neuromodulator
Description: Subjects will be treated with a range of hyaluronic acid-based soft tissue fillers (Restylane line) and Dysport neuromodulator
Study: NCT04743791

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).
Study: NCT06365619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Two cycles of neoadjuvant ipilimumab prior to surgical resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: two cycles of neoadjuvant nivolumab prior to surgical resection.
Study: NCT05465083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lungpacer AeroPace Protect System
Description: AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
Study: NCT05734638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIM-DASH
Description: Randomized participants will receive the MIM DASH, MIM or DASH intervention in eight weekly, 1-hour group sessions via telehealth (video and telephone access). Participants will receive session materials such as PowerPoint presentations so they can follow along by phone or videoconferencing. After completion of the eight weekly sessions, the participants will receive one follow-up call every other week for 8 weeks. The 3- and 6-month data will be collected as listed in the study AIMs. A manual of operations will detail all procedures related to the protocol, including participant recruitment, data collection, database usage, and database management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIM Only
Description: The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers. To avoid cross contamination, the interventionist will not also deliver the intervention to the MIM DASH group. Each participant will have access to the digital meditations with mindfulness practice recordings as well as a weekly diary to document study activities. Participants will be instructed to perform mindfulness meditations at least five times a week and record the time in their diary. After completion of the eight weekly sessions, these participants will receive six coaching calls (two per month for 3 months) focused on mindfulness practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH Only
Description: The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles.
Study: NCT05797610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7434656
Description: RO7434656 will be administered subcutaneously per schedule as specified.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously per schedule as specified.
Study: NCT06347874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESP Catheter
Description: an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed intermittent bolus.
Study: NCT05488145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive application intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: PROMIS medication adherence questionnaire is a well-defined self-report measure of medication-taking habits used to objectively assess adherence to medication and therapy. At the end of the study period, we will perform data analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Improvement in patient satisfaction will be measured by utilizing Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey scores. Surveys will be conducted among all participants at baseline and at 12 weeks, regardless of their use of the app, to better understand any barriers to using the app and which aspects of the app were most useful to patients.
Study: NCT06081153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: See arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description.
Study: NCT06142773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tidal Volume set on ventilator
Description: Mechanically ventilated patients who are undergoing MRI examinations under general anesthesia in isocapnic and isoxic conditions will have brain activity investigated under two different tidal volumes, 6 ml/kg and 12 ml/kg applied for 3-5 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal Volume set on ventilator
Description: Mechanically ventilated patients who are undergoing MRI examinations under general anesthesia in isocapnic and isoxic conditions will have brain activity investigated under two different tidal volumes, 6 ml/kg and 12 ml/kg applied for 3-5 minutes.
Study: NCT06335875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester Beverage
Description: Participants will consume ketone ester (KE) beverage, consisting of 19 g (=12.5 g active C8-KE) of Juvenescence Cognitive Switch™ diluted in water, twice per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Diet
Description: Participants will practice four dietary changes: 1. Not consuming sweets/candy, 2. Not consuming soda, 3. Replacing 'white' grains with complex carbohydrates such as brown rice or quinoa, and 4. Reserving any fruit consumption for the end of meals.
Study: NCT04972942

Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab
Description: Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)~2. Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~3. Maintenance: DARA every 4 weeks (Stop at Day +270)
Study: NCT06239389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide 100mg
Description: Thalidomide is available in capsulated form in the strength of 100 mg and 50 mg. It was given according to the weight of the patient. Due to somnolence, it was advised to give at night only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea is available in capsulated form under the brand of hydrea. Its available strength is 500 mg . Dosing depends upon weight of patient, that is 15mg/kg/day. so patients unable to take full capsule due to low weight, was advised to take hydroxyurea syrup.
Study: NCT06012422

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation group
Description: Elderly individuals will be evaluated once, by face-to-face interview method.
Study: NCT06193772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered psychodynamic therapy (IPDT)
Description: IPDT consists of 8 therapist-supported self-help modules delivered over 10 weeks on a secure online platform. Modules consist of texts and video followed by assignments which they send to their therapist and receive feedback within a few days. The intervention IPDT adapted starts with therapist feedback about the patient's predicted progress and continues with adapting the treatment to the individual adolescent, for example adding text chat sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered psychodynamic therapy (IPDT)
Description: IPDT consists of 8 therapist-supported self-help modules delivered over 10 weeks on a secure online platform. Modules consist of texts and video followed by assignments which they send to their therapist and receive feedback within a few days. The intervention IPDT adapted starts with therapist feedback about the patient's predicted progress and continues with adapting the treatment to the individual adolescent, for example adding text chat sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered psychodynamic therapy (IPDT)
Description: IPDT consists of 8 therapist-supported self-help modules delivered over 10 weeks on a secure online platform. Modules consist of texts and video followed by assignments which they send to their therapist and receive feedback within a few days. The intervention IPDT adapted starts with therapist feedback about the patient's predicted progress and continues with adapting the treatment to the individual adolescent, for example adding text chat sessions.
Study: NCT05446285

Intervention type: OTHER
Intervention: Clinical assessment
Description: All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)

Intervention type: OTHER
Intervention: Clinical assessment
Description: All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
Study: NCT05021653

Intervention type: OTHER
Intervention: no intervention
Description: No intervention involved

Intervention type: OTHER
Intervention: no intervention
Description: No intervention involved
Study: NCT05278468

Intervention type: OTHER
Intervention: PCR test for covid-19
Description: real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.

Intervention type: OTHER
Intervention: PCR test for covid-19
Description: real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
Study: NCT06227650

Intervention type: DEVICE
Intervention: hybrid closed loop insulin delivery system
Description: Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
Study: NCT06202859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIE
Description: Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIE
Description: Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
Study: NCT05171907

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teleobesity
Description: Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
Study: NCT05058989

Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)
Description: PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).

Intervention type: OTHER
Intervention: Clinical interventions and procedures
Description: First trimester (0-13 weeks):~* Consent~* Clinical data collection~* Blood samples (genomic+ hormonal)~* Duplex ultrasound~* Vector flow imaging (advanced ultrasound software)~* Truncated cone tool (measuring leg circumference using a tape measure)~* PPG~* AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~* Clinical data collection~* Blood sample (hormonal only)~* DUS~* VFI~* Truncated cone tool~* PPG~* AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester
Study: NCT05390606

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Flourish HEC and BioGenesis
Description: Flourish HEC is a 3-component system, including: 1) Balance feminine wash, used daily; 2) BioNourish vaginal moisturizer, used daily before bed except if having intercourse; 3) BiopHresh homeopathic vaginal suppository with probiotics, used once every 3 days before bed except if having intercourse. BioNourish is a class II medical device with FDA 510k clearance, on the market for 2 years. BioGenesis is also a class II medical device with FDA 510k clearance, and is designated as a fertility lubricant, safe for sperm and embryos.
Study: NCT05465395

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Cervical Adjustemnt
Description: Upper cervical adjustement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Cervical Adjustemnt
Description: Upper cervical adjustement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Adjustemnt
Description: Thoracic adjustment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Adjustemnt
Description: Thoracic adjustment
Study: NCT06550726

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Subjects will undergo MRI scanning in our 3T machine with dedicated high resolution sequences (including 2D T1-weighted inversion recovery sequences, 3D FLAIR MRI whole brain, 3D T1-weighted Sagittal MPRAGE; plus other sequences for the clinical purpose of pre-operative planning as per consensus with referring doctor)
Study: NCT06551896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib and immune checkpoint inhibitors
Study: NCT05441982

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Nutritive Sweetener Intake and impact on glucose homeostasis
Description: Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
Study: NCT05991934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention messages
Description: Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
Study: NCT06076395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA (Laryngeal Mask Airway)
Description: Pressure controlled versus Volume controlled ventilation using LMA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA (Laryngeal Mask Airway)
Description: Pressure controlled versus Volume controlled ventilation using LMA
Study: NCT06650189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Recorded music created by a certified music therapist
Study: NCT06180031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block using bupivicaine and magnesium sulphate
Description: This technique involves the deposition of the local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus